Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 10/20 | 0.74 |
| ▸ | POLB | P06746 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | BLM | P54132 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.48 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21729810 | 0.90 | NQO2 (0.56) | NQO2POLBALDH1A1RAB9AKDM4E | |
| SCHEMBL26022524 | 0.82 | NQO2 (0.50) | NQO2POLBALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL21497948 | 0.81 | NQO2 (0.61) | NQO2POLBALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL26021297 | 0.81 | NQO2 (0.47) | NQO2POLBRAB9AKDM4ENPC1 | |
| SCHEMBL11205485 | 0.80 | NQO2 (0.45) | NQO2POLBALDH1A1KDM4EMEN1 | |
| SCHEMBL2367850 | 0.79 | NQO2 (0.62) | NQO2POLBALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL29489945 | 0.79 | NQO2 (0.62) | NQO2POLBALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL30092589 | 0.78 | TLR8 (0.51) | NQO2POLBALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL21723154 | 0.77 | NQO2 (0.45) | NQO2POLBALDH1A1KDM4EMEN1 | |
| SCHEMBL19260544 | 0.77 | MAOA (0.53) | NQO2POLBALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263384-A9 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | CMBLU ENERGY AG (DE) | 2025-08-21 | — | — | US | disclosed |
| US-20240124405-A1 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | CMBLU PROJECKT AG (DE) | 2024-04-18 | — | — | US | disclosed |
| US-11731945-B2 | Redox-active compounds and uses thereof | CMBLU ENERGY AG (DE) | 2023-08-22 | — | — | US | disclosed |
| US-11731945-B2 | Redox-active compounds and uses thereof | CMBLU ENERGY AG (DE) | 2023-08-22 | — | — | US | disclosed |
| US-11731945-B2 | Redox-active compounds and uses thereof | CMBLU ENERGY AG (DE) | 2023-08-22 | — | — | US | disclosed |
| US-20210253540-A1 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | CMBLU PROJEKT AG (DE) | 2021-08-19 | — | — | US | disclosed |
| US-20210253540-A1 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | CMBLU PROJEKT AG (DE) | 2021-08-19 | — | — | US | disclosed |
| CN-113166079-A | Redox active compounds and their use | 克姆布鲁项目公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3837246-A2 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | CMBlu Projekt AG (DE) | 2021-06-23 | — | — | EP | disclosed |
| WO-2020035548-A2 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | CMBLU PROJEKT AG (DE) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020035548-A2 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | CMBLU PROJEKT AG (DE) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124405-A1 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | NOX4, NQO1, GPX1 | NQO2 519/4885POLB 476/4885ALDH1A1 277/4885 |
| US-20250263384-A9 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | NOX4, NQO1, GPX1 | NQO2 519/4885POLB 476/4885ALDH1A1 277/4885 |
| US-11731945-B2 | Redox-active compounds and uses thereof | NOX4, NQO1, GPX1 | NQO2 519/4885POLB 476/4885ALDH1A1 277/4885 |
| US-20210253540-A1 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | NOX4, NQO1, GPX1 | NQO2 519/4885POLB 476/4885ALDH1A1 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.